

GlyTech, Inc. Enters Into Collaborative Aptamer Glycosylation Research Agreement With TAGCyx Biotechnologies

2019/10/10

GlyTech, Inc. (CEO: Hiroaki Asai, Head office: Kyoto) has signed a collaborative research agreement with TAGCyx Biotechnologies (CEO: Dr. Chizuko Koseki, Head office: Tokyo) in relation to glycosylation techniques for aptamer therapeutics.

GlyTech possesses a unique platform for the production of an extensive variety of highly purified human N-glycans, and the technology to attach them to a specific site on target molecules such as synthetic peptides, while TAGCyx Biotechnologies possesses a leading, proprietary artificial nucleic acid base pair technology, used to produce high affinity and selective “Xenoligo®” DNA aptamers.

Modifying Xenoligo® with GlyTech’s glycosylation technology is expected to increase the functionality of aptamers and add high value to them.

Mr. Hiroaki Asai, President and CEO of GlyTech, Inc. commented “Research and development into medium molecular weight drugs has spread from its peptide drug beginnings to oligonucleotide therapeutics. As a developer of glycans as drug discovery materials for medium and high molecular weight drugs, we are looking forward to opening up new drug discovery possibilities using advanced artificial nucleobases and glycans.”

###